INVENTIVA (EPA:IVA) Inventiva announces a late breaker abstract from LEGEND, Phase 2 trial, evaluating lanifibranor in combination with empagliflozin in MASH at the AASLD The Liver Meeting® 2024
Transparency directive : regulatory news
21/10/2024 14:30
source : webdisclosure.com
INVENTIVA 's latest news
21/11/2024 22:00
20/11/2024 22:00
20/11/2024 22:00
15/11/2024 22:00
30/10/2024 21:00
21/10/2024 14:30
14/10/2024 19:45
31/07/2024 22:00
25/07/2024 22:00
18/07/2024 08:30
Other stories
05/12/2024 23:56
06/12/2024 00:49
05/12/2024 21:11
05/12/2024 23:47
06/12/2024 01:16
06/12/2024 00:36
05/12/2024 16:37
05/12/2024 21:52
05/12/2024 17:32
05/12/2024 21:30
05/12/2024 19:40
05/12/2024 11:27
06/12/2024 00:20
05/12/2024 16:56
05/12/2024 16:16
05/12/2024 18:18
05/12/2024 19:48
05/12/2024 11:01
05/12/2024 22:13
05/12/2024 14:04
05/12/2024 15:00
05/12/2024 18:00
05/12/2024 20:16
05/12/2024 20:29
03/12/2024 16:23
06/12/2024 01:37
05/12/2024 19:11
06/12/2024 00:35
06/12/2024 00:07
05/12/2024 21:45
05/12/2024 23:27
04/12/2024 19:20
04/12/2024 16:46
05/12/2024 14:36
05/12/2024 20:43
05/12/2024 23:25
05/12/2024 16:40
05/12/2024 13:21